Trial
NCT03498612
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
Merck Sharp & Dohme LLC
Condition
Follicular Lymphoma
Intervention
Laboratory Biomarker Analysis
Why stopped
Closed per SRC Low Accrual Policy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-12